Acute Myeloid Leukemia Risk Factors ID'd in Texas Adults

Acute Myeloid Leukemia Risk Factors ID'd in Texas Adults
Acute Myeloid Leukemia Risk Factors ID'd in Texas Adults

(HealthDay News) -- Solvent exposure, smoking, and obesity are significant risk factors for de novo acute myeloid leukemia (AML) in Texas, according to a study published online Feb. 1 in Cancer.

To investigate associations between lifestyle characteristics and AML risk, Sara S. Strom, Ph.D., of the University of Texas M.D. Anderson Cancer Center in Houston, and colleagues used questionnaires to collect demographic and occupational characteristics on 638 adults with de novo AML and 636 matched controls.

The researchers found that AML risk was significantly increased among men exposed to low or moderate/high levels of occupational solvents (odds ratio [OR], 2.87 and 4.13, respectively), or men who were heavy smokers (≥30 pack-years; OR, 1.86). For women, there was a significantly increased risk of AML with exposure to low or moderate/high levels of solvent (OR, 2.73 and 3.90, respectively), or for those who were obese (OR 1.62). Obesity correlated with a significantly increased risk of AML with recurrent cytogenetic abnormalities (RCA) (OR, 3.15). Solvent exposure at low or moderate/high levels correlated with a significantly increased risk of AML-RCA or AML with multilineage dysplasia (low level OR, 4.11 and 2.54, respectively, and moderate/high level OR, 5.13 and 3.02, respectively). There was a joint effect of smoking and solvent exposure, with the highest risk seen for smokers who were exposed to solvents (OR, 4.51).

"These findings highlight the need for multicenter collaborations to identify the epidemiologic and genetic risk factors associated with AML development to better understand the complexity of AML etiology and the underlying heterogeneity of the disease," the authors write.

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

ASCO: Combo Antibody Therapy Effective for Melanoma

ASCO: Combo Antibody Therapy Effective for Melanoma

Findings from a phase I study of concurrent ipilimumab and nivolumab for advanced melanoma

Nonmelanoma Skin Cancer Tied to Lower Alzheimer's Risk

Nonmelanoma Skin Cancer Tied to Lower Alzheimer's Risk

Older individuals with nonmelanoma skin cancer seem to have a significantly reduced risk of developing Alzheimer's disease, according to a Neurology study.

CLL study examines Obinutuzumab in reducing disease progression

Genetech announced results from CLL11, a Phase 3 study of obinutuzumab (GA101), comparing the combination of either obinutuzumab or Rituxan and chlorambucil to chlorambucil alone in chronic lymphocytic leukemia (CLL).